Search in:

Breast Cancer: Targets and Therapy Volume 14, 2022 - Issue

Submit an article Journal homepage

Open access

970

Views

CrossRef citations to date

Altmetric

Review

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Nusayba A BagegniDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA

https://orcid.org/0000-0001-9322-2451

Andrew A DavisDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA

Katherine K CliftonDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA

Foluso O AdemuyiwaDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USACorrespondence[email protected]

Pages 113-123 | Published online: 29 Apr 2022

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (9)

Adil Parvez, Furqan Choudhary, Priyal Mudgal, Rahila Khan, Kamal A. Qureshi, Humaira Farooqi & Ashok Aspatwar. (2023) PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Frontiers in Immunology 14.
Crossref

Mohini Chaurasia, Romi Singh, Srija Sur & S. J. S. Flora. (2023) A review of FDA approved drugs and their formulations for the treatment of breast cancer. Frontiers in Pharmacology 14.
Crossref

Hyo Sook Han, Praveen Vikas, Ricardo L.B. Costa, Nusrat Jahan, Ammanuel Taye & Erica M. Stringer-Reasor. (2023) Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between. American Society of Clinical Oncology Educational Book:43.
Crossref

Zheng Zhang, Yadi Zhang, Chuanling Liu, Jiakang Shao, Yimeng Chen, Yimin Zhu, Li Zhang, Boyu Qin, Ziqing Kong, Xixi Wang, Yutong Wang, Deqin Huang, Liqun Liu, Yuxin Zhou, Ran Tao, Zengjie Yang, Mei Liu & Weihong Zhao. (2023) A real‐world study of immune checkpoint inhibitors in advanced triple‐negative breast cancer. Cancer Innovation 2:3, pages 172-180.
Crossref

Nancy Nisticò, Annamaria Aloisio, Antonio Lupia, Anna Maria Zimbo, Selena Mimmi, Domenico Maisano, Rossella Russo, Fabiola Marino, Mariangela Scalise, Emanuela Chiarella, Teresa Mancuso, Giuseppe Fiume, Daniela Omodei, Antonella Zannetti, Giuliana Salvatore, Ileana Quinto & Enrico Iaccino. (2023) Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype. Cells 12:7, pages 1078.
Crossref

Frida Björk Gunnarsdottir, Pär-Ola Bendahl, Alexandra Johansson, Rui Benfeitas, Lisa Rydén, Caroline Bergenfelz & Anna-Maria Larsson. (2023) Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study. Breast Cancer Research 25:1.
Crossref

Nicoletta Cordani, Daniela Lisini, Valentina Coccè, Giuseppe Paglia, Ramona Meanti, Maria Grazia Cerrito, Pietro Tettamanti, Luca Bonaffini, Francesca Paino, Giulio Alessandri, Angela Marcianti, Aldo Giannì, Chiara Villa, Mario Mauri, Luca Mologni, Antonio Torsello, Augusto Pessina & Marina Elena Cazzaniga. (2023) Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC). International Journal of Molecular Sciences 24:6, pages 5864.
Crossref

Jinyao Wu, Yaokun Chen, Lingzhi Chen, Zeqi Ji, Huiting Tian, Daitian Zheng, Qiuping Yang, Yiyuan Liu, Jiehui Cai, Jiehua Zheng, Yexi Chen & Zhiyang Li. (2023) Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis. Frontiers in Oncology 12.
Crossref

Li Pan, Xiang Chen, Feyruz Virgilia Rassool, Chenglong Li & Jiayuh Lin. (2022) LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells. Biomedicines 10:8, pages 2003.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Articles from other publishers (9)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Citations (9)

Articles from other publishers (9)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date